Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.
The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.
BioLineRx Ltd. director Aharon Schwartz filed an initial ownership report showing direct holdings of 3,705,000 Ordinary Shares. He also holds multiple fully vested and time-vested employee stock options under the company’s 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.92 per share and expirations extending through 2034. A large October 2024 grant covers 2,055,000 underlying Ordinary Shares, of which 856,200 were vested at appointment and the remaining 1,198,800 are scheduled to vest in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. filed an Amendment No. 1 to its Form 20-F for the fiscal year ended December 31, 2025. The amendment is limited to correcting the date referenced in the consent of its independent auditor, Kesselman & Kesselman, a member firm of PwC, filed as Exhibit 15.1.
Updated CEO and CFO certifications under Sections 302 and 906 of the Sarbanes-Oxley Act are included as new exhibits, as required for amendments. All other disclosures in the original annual report remain unchanged, and the amendment does not update events after the original filing.
BioLineRx Ltd. Chief Executive Officer Philip A. Serlin filed an initial ownership report detailing his equity position. He directly holds 5,131,800 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with exercise prices ranging from $0.2640 down to $0.0450, expiring between 2026 and 2033. Several option grants are fully vested, while the most recent grant includes options that will vest in quarterly installments, subject to his continued service.
BioLineRx Ltd. has begun a first‑in‑human Phase 1/2a study of GLIX1, an oral, first‑in‑class TET2 activator, for recurrent and progressive glioblastoma and other high‑grade glioma. GLIX1 aims to selectively disrupt DNA damage repair in cancer cells while sparing healthy tissue.
The Phase 1 portion is expected to enroll up to 30 patients to determine a maximum tolerated or recommended dose based on safety, pharmacokinetics/pharmacodynamics and early efficacy, with initial data anticipated in the first half of 2027. The Phase 2a expansion will test GLIX1 in multiple tumor cohorts and combinations, including with standard treatments such as PARP inhibitors.
The trial is led by world‑recognized GBM investigators at NYU Langone Health, Northwestern University and Moffitt Cancer Center, under a collaboration with Hemispherian AS. BioLineRx also highlights its approved product APHEXDA for stem cell mobilization in multiple myeloma and an ongoing Phase 2b study of motixafortide in metastatic pancreatic cancer.
BioLineRx Ltd. reported audited 2025 results and highlighted progress in its oncology and rare disease pipeline. Total revenues fell to $1,180 thousand in 2025 from $28,940 thousand in 2024, reflecting a sharp decline in license and product revenues. The loss attributable to owners narrowed to $1,175 thousand, versus $9,221 thousand in 2024, as operating loss decreased and non‑operating income supported results.
At December 31, 2025, cash and cash equivalents were $3,250 thousand and short-term deposits were $17,626 thousand, with total assets of $40,905 thousand and total equity of $23,345 thousand. Management expects to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of March 2026 and continues a Phase 2b motixafortide trial in metastatic pancreatic cancer, alongside commercialization of APHEXDA for stem cell mobilization in multiple myeloma.
BioLineRx, an Israeli biopharma focused on oncology and rare diseases, highlights a high-risk financial profile despite having its first approved drug, APHEXDA (motixafortide), on the market via partners. The company recorded net losses of $60.6 million in 2023, $9.2 million in 2024 and $2.0 million in 2025, with an accumulated deficit of $401 million as of December 31, 2025.
Cash, cash equivalents and short-term deposits totaled $20.9 million at year-end 2025, which management believes will fund operations into the first half of 2027, yet auditors included a going-concern warning. BioLineRx has a secured loan with BlackRock, having drawn $30 million and later amending terms in November 2024 to repay remaining principal and interest through December 1, 2027, with a minimum cash covenant of $4 million and 10% of future out‑licensing milestones applied to debt reduction.
Strategically, BioLineRx out‑licensed motixafortide rights in Asia in October 2023 and globally ex‑Asia (excluding solid tumors) in November 2024, shut down independent U.S. commercialization, and refocused on development. In September 2025 it entered a collaboration with Hemispherian for GLIX1 in glioblastoma and other cancers, while implementing a one‑for‑forty effective reverse ADS split via an ADS ratio change in January 2025.
BioLineRx Ltd. chief financial officer Zeevi Mali filed an initial ownership report listing his equity position in the company. The filing shows multiple employee stock option grants over several years under the 2003 Amended and Restated Share Incentive Plan, alongside direct holdings of 1,311,000 Ordinary Shares.
The disclosed options cover underlying Ordinary Shares at exercise prices ranging from $0.0060 to $0.2870, with expiration dates between 2026 and 2035. Earlier grants from 2016 through 2022 are fully vested, while a grant dated March 21, 2023 is partly vested and continues to vest quarterly, and a large grant dated November 19, 2025 had no vested options initially and will vest over a one-year cliff and then 12 quarterly installments, subject to continued service. Certain securities tied to the plan are required to be registered in the name of a trustee to qualify for Israeli tax benefits.
BioLineRx Ltd. director Barbara-Jean Anne Bormann-Kennedy filed an initial Form 3 reporting her employee stock option holdings. She lists multiple options to buy Ordinary Shares granted under the 2003 Amended and Restated Share Incentive Plan, with exercise prices such as $0.8370, $0.3560, and $0.0520 per share and expirations between 2026 and 2034. One grant for 2,055,000 underlying shares at an exercise price of $0.0520 per share expires on August 14, 2034; footnotes state that 856,200 of these options were vested as of October 1, 2024, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to her continued service.
BioLineRx Ltd. filed a Form 6-K as a foreign private issuer reporting that it released its financial results for the three and nine months ended September 30, 2025. The company is furnishing a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for this period. These materials, including the section titled “Financial Results for the Quarter Ended September 30, 2025,” are incorporated by reference into all of its effective registration statements under the Securities Act of 1933.